[1]Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: Profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590.
[2]Burguin A, Diorio C, Durocher F. Breast cancer treatments: Updates and new challenges[J]. J Pers Med, 2021, 11(8): 808.
[3]中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J].中国癌症杂志, 2021, 31(10): 954-1040.
[4]Yuan C, Jin F, Guo X, et al. Correlation analysis of breast cancer DWI combined with DCEMRI imaging features with molecular subtypes and prognostic factors[J]. J Med Syst, 2019, 43(4): 83.
[5]Cai S, Yao M, Cai D, et al. Association between digital breast tomosynthesis and molecular subtypes of breast cancer[J]. Oncol Lett, 2019, 17(3): 2669-2676.
[6]García Fernndez A, Chabrera C, García Font M, et al. Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification[J]. Clin Transl Oncol, 2015, 17(3): 238-246.
[7]Jia WJ, Jia HX, Feng HY, et al. HER2enriched tumors have the highest risk of local recurrence in Chinese patients treated with breast conservation therapy[J]. Asian Pac J Cancer Prev, 2014, 15(1): 315-320.
[8]Jiang S, Hong YJ, Zhang F, et al. Computeraided evaluation of the correlation between MRI morphology and immunohistochemical biomarkers or molecular subtypes in breast cancer[J]. Sci Rep, 2017, 7(1): 13818.
[9]PuigVives M, Sanchez MJ, SanchezCantalejo J, et al. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish populationbased study[J]. Gynecol Oncol, 2013, 130(3): 609-614.
[10]刘健, 陈心华, 李娜妮. Luminal A型乳腺癌辅助化疗研究进展[J]. 肿瘤学杂志, 2010, 16(9): 679-685.
[11]Hwang KT, Kim EK, Jung SH, et al. Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database[J]. Breast Cancer Res Treat, 2018, 169(2): 311-322.
[12]Babyshkina N, Vtorushin S, Dronova T, et al. Impact of estrogen receptor α on the tamoxifen response and prognosis in luminalAlike and luminalBlike breast cancer[J]. Clin Exp Med, 2019, 19(4): 547-556.
[13]van Steenhoven JEC, Kuijer A, van Diest PJ, et al. Conventional pathology versus gene signatures for assessing luminal A and B type breast cancers: Results of a prospective cohort study[J]. Genes (Basel), 2018, 9(5): 261.
[14]Xu Q, Shao Y, Zhang J, et al. Anterior gradient 3 promotes breast cancer development and chemotherapy response[J]. Cancer Res Treat, 2020, 52(1): 218-245.
[15]Jeong Y, Bae SY, You D, et al. EGFR is a therapeutic target in hormone receptorpositive breast cancer[J]. Cell Physiol Biochem, 2019, 53(5): 805-819.
[16]Mangone L, Mancuso P, Tagliabue G, et al. Neoadjuvant therapy for breast cancer[J]. Tumori, 2019, 105(6): 488-493.
[17]Loibl S, Gianni L. HER2positive breast cancer[J]. Lancet, 2017, 389(10087): 2415-2429.
[18]Filho OM, Viale G, Stein S, et al. Impact of HER2 heterogeneity on treatment response of earlystage HER2positive breast cancer: Phase Ⅱ neoadjuvant clinical trial of TDM1 combined with pertuzumab[J]. Cancer Discov, 2021, 11(10): 2474-2487.
[19]Wuerstlein R, Harbeck N. Neoadjuvant therapy for HER2positive breast cancer[J]. Rev Recent Clin Trials, 2017, 12(2): 81-92.
[20]Zhao M, Scott S, Evans KW, et al. Combining neratinib with CDK4/6, mTOR, and MEK inhibitors in models of HER2positive cancer[J]. Clin Cancer Res, 2021, 27(6): 1681-1694.
[21]Pernas S, BarrosoSousa R, Tolaney SM. Optimal treatment of early stage HER2positive breast cancer[J]. Cancer, 2018, 124(23): 4455-4466.
[22]Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triplenegative breast cancer (keynote355): A randomised, placebocontrolled, doubleblind, phase 3 clinical trial[J]. Lancet, 2020, 396(10265): 1817-1828.
[23]Geenen JJJ, Linn SC, Beijnen JH, et al. PARP inhibitors in the treatment of triplenegative breast cancer[J]. Clin Pharmacokinet, 2018, 57(4): 427-437.
[24]Schmid P, Abraham J, Chan S, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as firstline therapy for metastatic triplenegative breast cancer: The PAKT trial[J]. J Clin Oncol, 2020, 38(5): 423-433.
[25]Lotter W, Diab AR, Haslam B, et al. Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotationefficient deep learning approach[J]. Nat Med, 2021, 27(2): 244-249.
[26]Sezgin G, Apaydin M, Etit D, et al. Tumor size estimation of the breast cancer molecular subtypes using imaging techniques[J]. Med Pharm Rep, 2020, 93(3): 253-259.
[27]Castaneda CA, Andres E, Barcena C, et al. Behaviour of breast cancer molecular subtypes through tumour progression[J]. Clin Transl Oncol, 2012, 14(6): 481-485.
[28]Mariscotti G, Durando M, Houssami N, et al. Digital breast tomosynthesis as an adjunct to digital mammography for detecting and characterising invasive lobular cancers: A multireader study[J]. Clin Radiol, 2016, 71(9): 889-895.
[29]Menezes GLG, Mann RM, Meeuwis C, et al. Optoacoustic imaging of the breast: Correlation with histopathology and histopathologic biomarkers[J]. Eur Radiol, 2019, 29(12): 6728-6740.
[30]Borri F, Granaglia A. Pathology of triple negative breast cancer[J]. Semin Cancer Biol, 2021, 72: 136-145.
[31]Tagliafico AS, Bignotti B, Rossi F, et al. Breast cancer Ki67 expression prediction by digital breast tomosynthesis radiomics features[J]. Eur Radiol Exp, 2019, 3(1): 36.
[32]Kamranzadeh H, Ardekani RM, Kasaeian A, et al. Association between Ki67 expression and clinicopathological features in prognosis of breast cancer: A retrospective cohort study[J]. J Res Med Sci, 2019, 24: 30.
[33]Peng Y, Wu S, Yuan G, et al. A radiomics method to classify microcalcification clusters in digital breast tomosynthesis[J]. Med Phys, 2020, 47(8): 3435-3446.
[34]Li Y, Cao J, Zhou Y, et al. Mammographic castingtype calcification is an independent prognostic factor in invasive breast cancer[J]. Sci Rep, 2019, 9(1): 10544.
[35]Kala C, Athar M, Kala S, et al. Clinical and cytomorphological characterization of triple negative breast cancer[J]. J Cytol, 2019, 36(2): 84-88.
[36]Zhao X, Li J. Research on the correlation between ultrasonographic features of breast cancer and expressions of ER, CD34 and p53[J]. J BUON, 2018, 23(2): 372-377.
[37]Rossman AH, Catenacci M, Zhao C, et al. Threedimensionallyprinted anthropomorphic physical phantom for mammography and digital breast tomosynthesis with custom materials, lesions, and uniform quality control region[J]. J Med Imaging (Bellingham), 2019, 6(2): 021604.
[38]Kuwabara N, Takuwa H, Takeuchi M, et al. Can digital breast tomosynthesis improve identification of malignant calcifications?[J]. Radiol Phys Technol, 2020, 13(3): 249-255.
[39]Marra A, Viale G, Pileri SA, et al. Breast implantassociated anaplastic large cell lymphoma: A comprehensive review[J]. Cancer Treat Rev, 2020, 84: 101963.
[40]Harbeck N, Rastogi P, Martin M, et al. Adjuvant abemaciclib combined with endocrine therapy for highrisk early breast cancer: Updated efficacy and ki67 analysis from the monarche study[J]. Ann Oncol, 2021, 32(12): 1571-1581.
|